NeoGenomics, Inc. (OQ:NEO)

Business Focus: Medical & Diagnostic Laboratories

Sector:  Healthcare Industry:  Healthcare Facilities & Services
See Regulatory Filings on SEC
Company Contact
Address: 12701 Commonwealth Dr Ste 9
FORT MYERS FL 33913-8626
Tel: 1-239-6904239
IR: See website
Key People
Douglas M. VanOort
Chairman of the Board, Chief Executive Officer
Lawrence Martine Weiss
Chief Medical Officer
George A. Cardoza
President - Pharma Services Division
Robert J. Shovlin
President - Clinical Services Division
Kathryn B. McKenzie
Principal Accounting Officer, Vice President - Finance
Steven A. Ross
Chief Information Officer
John S. Park
Chief Marketing Officer
Stephanie Bywater
Chief Compliance Officer
William B. Bonello
Chief Strategy and Corporate Development Officer, Director Investor Relations
Jennifer M. Balliet
Chief Culture Officer
Business Overview
NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.
Financial Overview
For the nine months ended 30 September 2019, NeoGenomics, Inc. revenues increased 51% to $302M. Net income applicable to common stockholders decreased 70% to $1.7M. Revenues reflect Clinical testing segment increase of 52% to $267.8M, Pharma Services segment increase of 41% to $34.2M. Net income was offset by Sales and marketing increase of 64% to $35M (expense), Research and development increase from $446K to $6.4M (expense).
Employees: 1,500 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $3,457M as of Sep 30, 2019
Annual revenue (TTM): $378.44M as of Sep 30, 2019
EBITDA (TTM): $49.81M as of Sep 30, 2019
Net annual income (TTM): $2.06M as of Sep 30, 2019
Free cash flow (TTM): $18.29M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 104,145,895 as of Sep 30, 2019
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization